Medtronic plc (MDT)

NYQ – Real Time Price. Currency in USD

76.82

+2.28 (3.06%)

At close: May 12, 2026, 4:00 PM EDT

76.96

+0.14 (0.18%)

After-hours: May 12, 2026, 7:59 PM EDT

11.05.2026

Medtronic (MDT) Stock Drops Despite Market Gains: Important Facts to Note

In the closing of the recent trading day, Medtronic (MDT) stood at $74.54, denoting a -2.11% move from the preceding trading day.

10.05.2026

3 Stocks With Monster Potential to Hold Through the Next Decade of Uncertainty

Shipping giant United Parcel Service is facing new competition from Amazon, but it still has a great brand and turnaround appeal. Innovative protein-focused food maker Hormel Foods is starting to get back on track.

09.05.2026

Why Savvy Investors Are Loading Up on This Beaten-Down Stock

Medtronic is a large and diversified medical device company that is currently deeply out of favor on Wall Street. The company is working to improve its profitability and growth profile, with important new products starting to hit the market.

07.05.2026

Is It Worth Investing in Medtronic (MDT) Based on Wall Street's Bullish Views?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

06.05.2026

Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement

Payment fulfills previously disclosed funding commitment of $20 million and supports planned completion of the BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) evaluating Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) in patients with uncontrolled hypertension and an indication for a pacemaker as part of the strategic collaboration between Orchestra BioMed and Medtronic This payment, together with $15 million received from Ligand and announced separately, represents a total of $35 million in strategic capital received under previously disclosed agreements NEW HOPE, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced the receipt of a $20 million investment from Medtronic, plc.

05.05.2026

Medtronic (MDT) Stock Sinks As Market Gains: Here's Why

In the latest trading session, Medtronic (MDT) closed at $77.79, marking a -2.76% move from the previous day.

04.05.2026

Medtronic (MDT) Declines More Than Market: Some Information for Investors

Medtronic (MDT) closed the most recent trading day at $78.3, moving 2.13% from the previous trading session.

Videos

03.03.2026

Positive

3 Dividend Stocks for March 2026

23.01.2026

Neutral

Final Trades: Capital One, Medtronic, Transocean and Caterpillar

27.11.2025

Positive

Robotics can 'democratize good healthcare' worldwide: Medtronic CEO

Press releases

06.05.2026

Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement

30.04.2026

FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy

Atrioventricular Interval Modulation (“AVIM”) Therapy Food and Drug Administration (“FDA”) Breakthrough Device Designations span the broader population of patients with uncontrolled hypertension despite medication at increased cardiovascular risk and the specific pacemaker-indicated population being evaluated in the BACKBEAT Trial The addressable U.S. patient population for AVIM Therapy, based on the indications for use specified in its Breakthrough Device Designations, comprises over 7.7 million adults with hypertension despite medication Breakthrough Device Designation supports favorable reimbursement pathways, including potential eligibility for New Technology Add-on Payment (“NTAP”) and Transitional Pass-Through (“TPT”) payment, which can facilitate broader, more timely patient access and provider adoption NEW HOPE, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced that the FDA has granted a second Breakthrough Device Designation (“BDD”) for AVIM Therapy specific to patients with uncontrolled hypertension despite the use of anti-hypertensive medications, and an indication for a pacemaker.

28.04.2026

Medtronic announces CE Mark for Stealth AXiS™ surgical system

Following recent FDA clearances, Medtronic is accelerating access to integrated planning, navigation, and robotics platform across Europe GALWAY, Ireland, April 28, 2026 /PRNewswire/ -- Medtronic, a global leader in healthcare technology, has received CE mark for the Stealth AXiS™ surgical system, a next-generation platform that brings planning, navigation, and robotics together into one single, intelligent system. The Stealth AXiS™ system is indicated for spine and cranial procedures, highlighting the platform's scalability across multiple surgical specialties for Medtronic.

25.04.2026

Medtronic announces key Affera™ clinical study milestones for Sphere-9™ and Sphere-360™ catheters as global adoption continues

HRS late-breaking data: Interim results highlight six-month outcomes for patients treated with the Sphere-9 catheter for sustained monomorphic ventricular tachycardia (VT) Breakthrough device designation granted for use of the Sphere-9 catheter for treatment of VT; U.S. pivotal trial approved by FDA New at HRS: data show consistent durability for the Sphere-360 catheter across patient anatomies; Sphere-360 approved in CE Mark geographies First patients enrolled in Conquer-AF trial to evaluate the Sphere-9 catheter for repeat atrial fibrillation procedures GALWAY, Ireland and CHICAGO, April 25, 2026 /PRNewswire/ -- Medtronic plc, (NYSE: MDT), a global leader in healthcare technology, today announced continued momentum for the Affera™ family of technologies for cardiac arrhythmia treatment, including promising data presented at the Heart Rhythm Society (HRS) Annual Meeting and the start of a new trial to evaluate a broader population of atrial fibrillation (AFib) patients. With ongoing positive physician feedback and global commercial expansion, Medtronic continues to invest in clinical research to study the Affera mapping and ablation system for potential new indications.

Medtronic plc (MDT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Medtronic plc (MDT)

Medtronic (MDT) Stock Drops Despite Market Gains: Important Facts to Note

3 Stocks With Monster Potential to Hold Through the Next Decade of Uncertainty

Why Savvy Investors Are Loading Up on This Beaten-Down Stock

Is It Worth Investing in Medtronic (MDT) Based on Wall Street's Bullish Views?

Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement

Medtronic (MDT) Stock Sinks As Market Gains: Here's Why

Medtronic (MDT) Declines More Than Market: Some Information for Investors

Videos

Press releases

Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement

FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy

Medtronic announces CE Mark for Stealth AXiS™ surgical system

Medtronic announces key Affera™ clinical study milestones for Sphere-9™ and Sphere-360™ catheters as global adoption continues

Medtronic (MDT) Stock Drops Despite Market Gains: Important Facts to Note

3 Stocks With Monster Potential to Hold Through the Next Decade of Uncertainty

Why Savvy Investors Are Loading Up on This Beaten-Down Stock

Is It Worth Investing in Medtronic (MDT) Based on Wall Street's Bullish Views?

Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement

Medtronic (MDT) Stock Sinks As Market Gains: Here's Why

Medtronic (MDT) Declines More Than Market: Some Information for Investors

Videos

Press releases

Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement

FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy

Medtronic announces CE Mark for Stealth AXiS™ surgical system

Medtronic announces key Affera™ clinical study milestones for Sphere-9™ and Sphere-360™ catheters as global adoption continues

Search stocks

Medtronic plc (MDT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Medtronic plc (MDT)

Medtronic (MDT) Stock Drops Despite Market Gains: Important Facts to Note

3 Stocks With Monster Potential to Hold Through the Next Decade of Uncertainty

Why Savvy Investors Are Loading Up on This Beaten-Down Stock

Is It Worth Investing in Medtronic (MDT) Based on Wall Street's Bullish Views?

Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement

Medtronic (MDT) Stock Sinks As Market Gains: Here's Why

Medtronic (MDT) Declines More Than Market: Some Information for Investors

Videos

Press releases

Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement

FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy

Medtronic announces CE Mark for Stealth AXiS™ surgical system

Medtronic announces key Affera™ clinical study milestones for Sphere-9™ and Sphere-360™ catheters as global adoption continues

Medtronic (MDT) Stock Drops Despite Market Gains: Important Facts to Note

3 Stocks With Monster Potential to Hold Through the Next Decade of Uncertainty

Why Savvy Investors Are Loading Up on This Beaten-Down Stock

Is It Worth Investing in Medtronic (MDT) Based on Wall Street's Bullish Views?

Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement

Medtronic (MDT) Stock Sinks As Market Gains: Here's Why

Medtronic (MDT) Declines More Than Market: Some Information for Investors

Videos

Press releases

Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement

FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy

Medtronic announces CE Mark for Stealth AXiS™ surgical system

Medtronic announces key Affera™ clinical study milestones for Sphere-9™ and Sphere-360™ catheters as global adoption continues